3562-63-8 Usage
Uses
Used in Pharmaceutical Industry:
Megestrol is used as an oral contraceptive for the prevention of pregnancy. It works by inhibiting ovulation, altering the cervical mucus to make it less conducive for sperm survival, and altering the lining of the uterus to prevent implantation of a fertilized egg.
Used in Oncology:
Megestrol is used as an antineoplastic agent, particularly in the treatment of certain types of cancer. It is often prescribed for the management of anorexia, cachexia (wasting syndrome), and weight loss associated with advanced cancer, as well as for the treatment of endometrial cancer and breast cancer. Megestrol works by affecting the hormonal balance in the body, which can help slow down the growth of certain cancer cells.
Indications
As a representitive of the compounds of the class of progestins, this drug is used for various
forms of cancer, in particular cancer of the breast, kidneys, and others.
World Health Organization (WHO)
Megestrol acetate, a synthetic progestogen, was introduced in the
early 1960s as a component in oral contraceptive preparations. In 1967, as a result
of new regulations required by the United States Food and Drug Administration,
megestrol acetate was submitted to long-term toxicity studies and by the early
1970s it was shown to be associated with an increased incidence of mammary
tumours in beagle bitches which led to its withdrawal by several regulatory
authorities. Subsequently the validity of the beagle bitch model as a predictor of
carcinogenicity of steroid contraceptives has been contested by many national
regulatory authorities and megestrol remains available in some countries for
contraceptive purposes. In other countries its use is restricted to anticancer
treatment.
(Reference: (WHODI) WHO Drug Information, 1-3, 5-7, 1984)
Synthesis
Megestrol, 17α-hydroxy-6α-methylpregna-4,6-dien-3,20-dione acetate
(28.3.9), is a product of dehydrogenation medroxyprogesterone (28.3.7) with chloranil
(tetrachloro-p-benzoquinone) in the presence of p-toluenesulfonic acid, which results in
the formation of an additional double bond at position C6–C7, and subsequent acetylation
of the product (28.3.8) leads to the desired megestrol (28.3.9) by acetic anhydride in the
presence of p-toluenesulfonic acid.
Check Digit Verification of cas no
The CAS Registry Mumber 3562-63-8 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,5,6 and 2 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 3562-63:
(6*3)+(5*5)+(4*6)+(3*2)+(2*6)+(1*3)=88
88 % 10 = 8
So 3562-63-8 is a valid CAS Registry Number.
InChI:InChI=1/C24H32O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h12-13,18-20H,6-11H2,1-5H3/t18?,19?,20?,22?,23?,24-/m0/s1
3562-63-8Relevant articles and documents
Inhibitors of type 5 and type 3 17β-hydroxysteroid dehydrogenase and methods for their use
-
, (2008/06/13)
Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17β-hydroxysteroid dehydrogenase. Novel inhibitors of type 5 17β-hydroxysteroid dehydrogenase are also disclosed, as are novel inhibitors of type 3 17β-hydroxysteroid dehydrogenase.
Novel 17-esters of 17α-hydroxy gestogens, compositions containing such compounds, processes for their preparation and methods of treatment therewith
-
, (2008/06/13)
This invention relates to novel 17α-esters of gestogens having an antitumour activity and to the preparation thereof. The invention is also concerned with pharmaceutical compositions containing the said compounds, and method of treatment therewith.
